Ginkgo Bioworks Holdings (DNA) Other Gross PP&E Adjustments (2020 - 2026)
Ginkgo Bioworks Holdings posted quarterly Other Gross PP&E Adjustments of -$13.8 million for Q1 2026, up 62.04% year-on-year from -$8.5 million in Q1 2025, and down 145.08% on a QoQ basis from -$5.6 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$13.8 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 62.04% year-over-year to -$13.8 million; the trailing twelve-month figure through Mar 2026 stood at -$13.8 million (up 62.04% YoY), and the FY2025 full-year result was -$5.6 million, up 81.12% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$13.8 million, down from -$5.6 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at $269.6 million in Q3 2022 and bottomed at -$81.0 million in Q2 2024.
- The 5-year median for Other Gross PP&E Adjustments is -$5.6 million (2025), against an average of $41.6 million.
- The widest annual swing landed in 2023, when Other Gross PP&E Adjustments soared 1987.08%; it then sank 480.56% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$5.4 million in 2022, then jumped by 1987.08% to $102.1 million in 2023, then tumbled by 129.23% to -$29.8 million in 2024, then surged by 81.12% to -$5.6 million in 2025, then slumped by 145.08% to -$13.8 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$13.8 million (Q1 2026), -$5.6 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | -13.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.81 Mn |
| Mar 31, 2026 | -13.81 Mn |
| Dec 31, 2025 | -5.64 Mn |
| Dec 31, 2025 | -5.64 Mn |
| Sep 30, 2025 | -14.23 Mn |
| Sep 30, 2025 | -14.23 Mn |
| Jun 30, 2025 | -25.29 Mn |
| Jun 30, 2025 | -25.29 Mn |
| Mar 31, 2025 | -36.38 Mn |
| Mar 31, 2025 | -36.38 Mn |
| Dec 31, 2024 | -29.84 Mn |
| Dec 31, 2024 | -29.84 Mn |
| Sep 30, 2024 | -48.91 Mn |
| Sep 30, 2024 | -48.91 Mn |
| Jun 30, 2024 | -81.00 Mn |
| Jun 30, 2024 | -81.00 Mn |
| Mar 31, 2024 | 95.12 Mn |
| Mar 31, 2024 | 95.12 Mn |
| Dec 31, 2023 | 102.11 Mn |
| Dec 31, 2023 | 102.11 Mn |
| Sep 30, 2023 | -23.25 Mn |
| Sep 30, 2023 | -23.25 Mn |
| Jun 30, 2023 | 21.28 Mn |
| Jun 30, 2023 | 21.28 Mn |
| Mar 31, 2023 | 32.96 Mn |
| Mar 31, 2023 | 32.96 Mn |
| Dec 31, 2022 | -5.41 Mn |
| Dec 31, 2022 | -5.41 Mn |
| Sep 30, 2022 | 269.65 Mn |
| Sep 30, 2022 | 269.65 Mn |
| Jun 30, 2022 | 252.73 Mn |
| Jun 30, 2022 | 252.73 Mn |
| Mar 31, 2022 | 217.55 Mn |
| Mar 31, 2022 | 217.55 Mn |
| Dec 31, 2021 | 187.85 Mn |
| Dec 31, 2021 | 187.85 Mn |
| Sep 30, 2021 | 196.14 Mn |
| Sep 30, 2021 | 196.14 Mn |
| Dec 31, 2020 | 151.91 Mn |
| Dec 31, 2020 | 151.91 Mn |